Peptide Profile
Livagen
Lys-Glu-Asp-Glu · Liver bioregulator · Khavinson liver peptide
Livagen is a synthetic tetrapeptide classified as a Khavinson-class bioregulator targeted at liver and hepatocyte tissue, investigated for cytoprotective and anti-aging effects on hepatocellular gene expression and chromatin…
- Half-life
- Unknown
- Routes
- subcutaneous, intramuscular
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
What Livagen is
About Livagen
Tetrapeptide bioregulator for hepatocytes; activates gene expression in liver cells; promotes liver cell regeneration; restores lymphocyte activity via liver-mediated immune pathways
Livagen is a synthetic tetrapeptide classified as a Khavinson-class bioregulator targeted at liver and hepatocyte tissue, investigated for cytoprotective and anti-aging effects on hepatocellular gene expression and chromatin organization through proposed regulatory mechanisms analogous to other short Khavinson-class bioregulators. Like other Khavinson bioregulator peptides, livagen is proposed to modulate gene expression in target hepatocyte cells through epigenetic and transcriptional mechanisms, with tissue-specific targeting proposed to support hepatocyte function and liver regenerative capacity under conditions of aging-related cellular stress. Published research on Khavinson-class ultrashort peptides has characterized neuroepigenetic mechanisms of action in aging tissue models and demonstrated peptide regulation of cell differentiation in progenitor populations, providing the class-level mechanistic context for livagen's proposed hepatic regulatory effects. Livagen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives entirely from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals.
Livagen Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
What the evidence says about Livagen
Research Evidence
based on 2 studies · most recent 2022
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Not Evaluated
Russian liver peptide bioregulator (Lys-Glu-Asp-Gly) from Khavinson Institute. Studied for aging and hepatic function. No FDA approval, no NDA or IND. Research chemical in US.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
2 sources cited · 2 weak
2 Reviews
Bioavailability and Biological Activities of Food-Derived Di- and Tripeptides: In Silico and In Vitro Studies
International Journal of Molecular Sciences · 2022
This review examines the biological activities and transport mechanisms of ultrashort di- and tripeptides including livagen, documenting evidence for their immunomodulatory activity in lymphoid and hematopoietic tissues and transport via intestinal peptide transporters relevant to systemic bioavailability.
Short Peptides in the Treatment of Age-Related Diseases
Stem Cell Reviews and Reports · 2020
This review summarizes the geroprotective properties of short regulatory peptides including livagen, documenting their effects on hematopoietic and lymphoid tissue function and longevity in animal models, with discussion of clinical data showing reduced age-related pathology in human cohorts from the Khavinson research program.
Livagen Side Effects & Safety Considerations
Research-use compound with limited human data. Evidence strength varies — see the Evidence section.
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSLivagen
Frequently Asked Questions — Livagen
Livagen is a synthetic tetrapeptide classified as a Khavinson-class bioregulator targeted at liver and hepatocyte tissue, investigated for cytoprotective and anti-aging effects on hepatocellular gene expression and chromatin organization through proposed regulatory mechanisms analogous to other short Khavinson-class bioregulators. Like other Khavinson bioregulator peptides, livagen is proposed to modulate gene expression in target hepatocyte cells through epigenetic and transcriptional mechanisms, with tissue-specific targeting proposed to support hepatocyte function and liver regenerative capacity under conditions of aging-related cellular stress.
liver cell regeneration, hepatoprotection, immune restoration via liver, chromatin activation.
Research on Livagen primarily documents effects related to liver cell regeneration and hepatoprotection and immune restoration via liver and chromatin activation. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
For Livagen, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
2 providers in the directory currently offer Livagen.
Across 9 research vendors tracked on PeptideBase, Livagen has a median price of about $3.00 per mg, typically ranging $2.75–$3.15 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.
How to get Livagen
Market Pricing
9 vendorsPrice per mg varies by quantity, vendor type, and formulation. Research use only.
Data verified August 2026 · Livagen price intelligence
Where to buy Livagen
2 providersQuestions to ask your provider
Stay updated on Livagen providers
New providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Livagen — Per-mg Price Benchmark. Retrieved September 11, 2026, from https://peptidebase.io/peptides/livagen